XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC - Thailand PR News - [Banking](https://thailandbusinessnews.net/category/banking/) - [Companies](https://thailandbusinessnews.net/category/companies/) - [Economy](https://thailandbusinessnews.net/category/economy/) - [Press Releases](https://thailandbusinessnews.net/category/press-release/) - [PR Newswire](https://thailandbusinessnews.net/pr-newswire-updates/) - [Tech](https://thailandbusinessnews.net/category/tech/) - [Tourism](https://thailandbusinessnews.net/category/tourism/) - [Press Release](https://thailandbusinessnews.net/category/press-release/) # XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC ##### Up next ![CordenPharma Expands Peptide Platform with more than 500 Million Euro Greenfield Facility Construction in the Basel Region of Switzerland](https://i0.wp.com/r2.thailandbusinessnews.net/2025/03/CordenPharma_aerial_sketch_of_new_Peptide_Greenfield_Construction_near_Basel_Switzerland_2025_web.jp.jpeg?resize=200%2C110&ssl=1 "CordenPharma Expands Peptide Platform with more than 500 Million Euro Greenfield Facility Construction in the Basel Region of Switzerland") [](https://thailandbusinessnews.net/press-release/cordenpharma-expands-peptide-platform-with-more-than-500-million-euro-greenfield-facility-construction-in-the-basel-region-of-switzerland/) ###### [CordenPharma Expands Peptide Platform with more than 500 Million Euro Greenfield Facility Construction in the Basel Region of Switzerland](https://thailandbusinessnews.net/press-release/cordenpharma-expands-peptide-platform-with-more-than-500-million-euro-greenfield-facility-construction-in-the-basel-region-of-switzerland/) Published on 05 March 2025 ##### Author ##### [ CISION PRNewswire ](https://thailandbusinessnews.net/author/cision/) ##### Tags - [PRNewswire](https://thailandbusinessnews.net/tag/prnewswire/) ![](https://mma.prnasia.com/media2/2355066/ANTENGENE_EN_Logo.jpg?p=medium600 "logo") – XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia. – From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene’s commercial presence in APAC. To date, XPOVIO® has been approved for multiple indications in ten markets across the APAC region. – XPOVIO® has been approved for health insurance coverage in the mainland of China, Taiwan market, Australia, Singapore and South Korea. SHANGHAI and HONG KONG, March 5, 2025 /PRNewswire/ — Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that the Indonesia National Agency of Drug and Food Control (BPOM) has approved a New Drug Application (NDA) for XPOVIO® (selinexor) for three indications: (1) In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy;(2) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory MM (R/R MM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors (PIs), at least two immunomodulatory agents (IMiDs), and an anti‐CD38 monoclonal antibody; and (3) as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B‐cell lymphoma (R/R DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy who are not eligible for haematopoietic cell transplant. With a novel mechanism of action, XPOVIO® is the world’s first approved orally-available, selective XPO1 inhibitor, which has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea). The ASEAN region, with its steady economic growth and a population exceeding 600 million, has become a market of significant potential for global biomedical development. The accelerating aging population in ASEAN has increased the overall disease burden on patients and local communities, leading to a growing demand for novel therapeutics. Currently, Antengene is actively expanding its presence into APAC markets in efforts to introduce more innovative medicines to the ASEAN region in the future, improving the level of healthcare in these regions and benefiting more patients in need. While bringing XPOVIO® to more APAC markets, Antengene is also striving to expand the indications of XPOVIO®. Leveraging the drug’s novel mechanism of action, Antengene is currently developing multiple combination regimens of XPOVIO® for the treatment of various indications including myelofibrosis (MF) and endometrial cancer. About XPOVIO® (selinexor) XPOVIO® is the world’s first approved orally-available, selective inhibitor of the nuclear export protein XPO1. It offers a novel mechanism of action, synergistic effects in combination regimens, fast onset of action, and durable responses. By blocking the nuclear export protein XPO1, XPOVIO® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. XPOVIO® delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the intranuclear accumulation of tumor suppressor proteins; 2) reducing the level of oncogenic proteins in the cytoplasm by inducing the intranuclear accumulation of oncogenic mRNAs; 3) restoring hormone sensitivity by activating the glucocorticoid receptors (GR) pathway. To utilize its unique mechanism of actions, XPOVIO® is being evaluated for use in multiple combination regimens in a range of indications. At present, Antengene is conducting multiple clinical studies of XPOVIO® in the mainland of China for the treatment of relapsed/refractory hematologic malignancies and solid tumors (3 of these studies are being jointly conducted by Antengene and Karyopharm Therapeutics Inc. \[Nasdaq:KPTI\]). About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: [Donald.Lung@antengene.com ](mailto:Donald.Lung@antengene.com )Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Mobile: +86 13062747000 [Source link ](https://www.prnasia.com/story/archive/4602879_CN02879_0?rand=89749) ``` This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network ``` ##### You May Also Like [](https://thailandbusinessnews.net/press-release/ja-worldwide-launches-institute-to-drive-research-and-innovation/) ![JA Worldwide Launches Institute to Drive Research and Innovation](https://i0.wp.com/r2.thailandbusinessnews.net/2025/02/JA_Worldwide_launches_The_JA_Institute.jpg?resize=260%2C140&ssl=1 "JA Worldwide Launches Institute to Drive Research and Innovation") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## JA Worldwide Launches Institute to Drive Research and Innovation BOSTON, Feb. 12, 2025 /PRNewswire/ — JA Worldwide, one of the world’s… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - February 12, 2025 [](https://thailandbusinessnews.net/press-release/locksley-reports-high-grade-antimony-concentrate-at-significantly-higher-grades-than-comparable-american-projects-in-initial-metallurgical-test-work-of-surface-samples-from-the-companys-desert-a/) ## Locksley Reports High-Grade Antimony Concentrate at Significantly Higher Grades than Comparable American Projects in Initial Metallurgical Test Work of Surface Samples from the Company's Desert Antimony Mine Project in California SAN BERNARDINO, Calif., Oct. 8, 2025 /PRNewswire/ — Locksley Resources, (ASX: LKY;… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - October 8, 2025 [](https://thailandbusinessnews.net/press-release/nomad-esim-drives-global-connectivity-and-makes-travel-seamless/) ## Nomad eSIM Drives Global Connectivity and Makes Travel Seamless SANTA CLARA, Calif., May 7, 2025 /PRNewswire/ — Nomad eSIM, a business line… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - May 7, 2025 ##### Most Read - [![Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/chubb-wealth-debuts-evergreen-private-markets-fund-series-with-s64/ "Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64") [Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64](https://thailandbusinessnews.net/press-release/chubb-wealth-debuts-evergreen-private-markets-fund-series-with-s64/ "Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64") - [![Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/adecco-group-announces-salesforces-agentforce-coworker-rollout-across-40-countries/ "Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries") [Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries](https://thailandbusinessnews.net/press-release/adecco-group-announces-salesforces-agentforce-coworker-rollout-across-40-countries/ "Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries") - [![JBD Launches the "Roadrunner" Platform: MicroLED Microdisplays with 2.5-μm Pixel Pitch](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/jbd-launches-the-roadrunner-platform-microled-microdisplays-with-2-5-%ce%bcm-pixel-pitch/ "JBD Launches the "Roadrunner" Platform: MicroLED Microdisplays with 2.5-μm Pixel Pitch") [JBD Launches the "Roadrunner" Platform: MicroLED Microdisplays with 2.5-μm Pixel Pitch](https://thailandbusinessnews.net/press-release/jbd-launches-the-roadrunner-platform-microled-microdisplays-with-2-5-%ce%bcm-pixel-pitch/ "JBD Launches the "Roadrunner" Platform: MicroLED Microdisplays with 2.5-μm Pixel Pitch") - [![Agoda Reveals Sustained Intra-Regional Travel Interest Across Southeast Asia](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/agoda-reveals-sustained-intra-regional-travel-interest-across-southeast-asia/ "Agoda Reveals Sustained Intra-Regional Travel Interest Across Southeast Asia") [Agoda Reveals Sustained Intra-Regional Travel Interest Across Southeast Asia](https://thailandbusinessnews.net/press-release/agoda-reveals-sustained-intra-regional-travel-interest-across-southeast-asia/ "Agoda Reveals Sustained Intra-Regional Travel Interest Across Southeast Asia") - [![INVT to Showcase Power and Liquid-Cooling Solutions for Data Center Modernization at Data Centre World Asia 2026](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/invt-to-showcase-power-and-liquid-cooling-solutions-for-data-center-modernization-at-data-centre-world-asia-2026/ "INVT to Showcase Power and Liquid-Cooling Solutions for Data Center Modernization at Data Centre World Asia 2026") [INVT to Showcase Power and Liquid-Cooling Solutions for Data Center Modernization at Data Centre World Asia 2026](https://thailandbusinessnews.net/press-release/invt-to-showcase-power-and-liquid-cooling-solutions-for-data-center-modernization-at-data-centre-world-asia-2026/ "INVT to Showcase Power and Liquid-Cooling Solutions for Data Center Modernization at Data Centre World Asia 2026") - [![Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/triton-uranium-advances-atlas-project-reports-exploration-target-of-46-56-million-pounds-of-uranium/ "Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium") [Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium](https://thailandbusinessnews.net/press-release/triton-uranium-advances-atlas-project-reports-exploration-target-of-46-56-million-pounds-of-uranium/ "Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium") ##### Subscribe via Email Enter your email address to subscribe and receive notifications of new posts by email. Email Address Subscribe [](https://thailandbusinessnews.net/press-release/wan-aichef-ultra-earns-2026-idea-recognition-rethinking-ai-cooking-for-everyday-life/) ![WAN AICHEF ULTRA Earns 2026 IDEA Recognition, Rethinking AI Cooking for Everyday Life](https://i0.wp.com/mmx.prnasia.com/media/MS1990610/20260917014815EDT_image_1.jpg?resize=260%2C140&ssl=1 "WAN AICHEF ULTRA Earns 2026 IDEA Recognition, Rethinking AI Cooking for Everyday Life") ## WAN AICHEF ULTRA Earns 2026 IDEA Recognition, Rethinking AI Cooking for Everyday Life A Load and Go Cooking Experience Designed Around Real Household Use LAS… [](https://thailandbusinessnews.net/press-release/a-robust-adjusted-ebit-margin-of-18-8-driven-by-solid-organic-revenue-growth-of-7-4/) ![A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%](https://i0.wp.com/mmx.prnasia.com/media/MS1988977/VBD_01.jpg?resize=260%2C140&ssl=1 "A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%") ## A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4% PARIS, Sept. 18, 2026 /PRNewswire/ — Virbac Headquarters, Carros, France H1… [](https://thailandbusinessnews.net/press-release/tdh-holdings-announces-its-annual-general-meeting-of-shareholders-will-be-held-on-november-10-2026/) ## TDH Holdings Announces its Annual General Meeting of Shareholders will be Held on November 10, 2026 BEIJING, Sept. 18, 2026 /PRNewswire/ — TDH Holdings, Inc. (NASDAQ: PETZ)… [](https://thailandbusinessnews.net/press-release/advancion-releases-2025-sustainability-report-safe-by-choice-sustainable-by-design/) ## ADVANCION RELEASES 2025 SUSTAINABILITY REPORT: "SAFE BY CHOICE. SUSTAINABLE BY DESIGN." Advancion’s fifth annual report highlights the Company’s progress in…